J Satoh1, H Tabunoki, T Ishida, Y Saito, K Arima. 1. Department of Bioinformatics and Molecular Neuropathology, Meiji Pharmaceutical University, Tokyo, Japan.
Abstract
AIMS: Ubiquilin-1 acts as an adaptor protein that mediates the translocation of polyubiquitinated proteins to the proteasome for degradation. Although previous studies suggested a key role of ubiquilin-1 in the pathogenesis of Alzheimer's disease (AD), a direct relationship between ubiquilin-1 and Hirano bodies in AD brains remains unknown. METHODS: By immunohistochemistry, we studied ubiquilin-1 and ubiquilin-2 expression in the frontal cortex and the hippocampus of six AD and 13 control cases. RESULTS: Numerous Hirano bodies, accumulated in the hippocampal CA1 region of AD brains, expressed intense immunoreactivity for ubiquilin-1. They were much less frequently found in control brains. However, Hirano bodies did not express a panel of markers for proteasome, autophagosome or pathogenic proteins, such as ubiquilin-2, ubiquitin, p62, LC3, beclin-1, HDAC6, paired helical filament (PHF)-tau, protein-disulphide isomerase (PDI) and phosphorylated TDP-43, but some of them expressed C9orf72. Ubiquilin-1-immunoreactive deposits were classified into four distinct morphologies, such as rod-shaped structures characteristic of Hirano bodies, dystrophic neurites contacting senile plaques, fragmented structures accumulated in the lesions affected with severe neuronal loss, and thread-shaped structures located mainly in the molecular layer of the hippocampus. CONCLUSIONS: Ubiquilin-1 immunoreactivity is concentrated on Hirano bodies and dystrophic neurites in AD brains, suggesting that aberrant expression of ubiquilin-1 serves as one of pathological hallmarks of AD.
AIMS: Ubiquilin-1 acts as an adaptor protein that mediates the translocation of polyubiquitinated proteins to the proteasome for degradation. Although previous studies suggested a key role of ubiquilin-1 in the pathogenesis of Alzheimer's disease (AD), a direct relationship between ubiquilin-1 and Hirano bodies in AD brains remains unknown. METHODS: By immunohistochemistry, we studied ubiquilin-1 and ubiquilin-2 expression in the frontal cortex and the hippocampus of six AD and 13 control cases. RESULTS: Numerous Hirano bodies, accumulated in the hippocampal CA1 region of AD brains, expressed intense immunoreactivity for ubiquilin-1. They were much less frequently found in control brains. However, Hirano bodies did not express a panel of markers for proteasome, autophagosome or pathogenic proteins, such as ubiquilin-2, ubiquitin, p62, LC3, beclin-1, HDAC6, paired helical filament (PHF)-tau, protein-disulphide isomerase (PDI) and phosphorylated TDP-43, but some of them expressed C9orf72. Ubiquilin-1-immunoreactive deposits were classified into four distinct morphologies, such as rod-shaped structures characteristic of Hirano bodies, dystrophic neurites contacting senile plaques, fragmented structures accumulated in the lesions affected with severe neuronal loss, and thread-shaped structures located mainly in the molecular layer of the hippocampus. CONCLUSIONS:Ubiquilin-1 immunoreactivity is concentrated on Hirano bodies and dystrophic neurites in AD brains, suggesting that aberrant expression of ubiquilin-1 serves as one of pathological hallmarks of AD.
Authors: Li Zeng; Bo Wang; Sean A Merillat; Eiko N Minakawa; Matthew D Perkins; Biswarathan Ramani; Sara J Tallaksen-Greene; Maria do Carmo Costa; Roger L Albin; Henry L Paulson Journal: Neurobiol Dis Date: 2015-06-30 Impact factor: 5.996
Authors: Huilin Gong; Weijiang Dong; Steven W Rostad; Santica M Marcovina; John J Albers; John D Brunzell; Simona Vuletic Journal: J Histochem Cytochem Date: 2013-09-04 Impact factor: 2.479
Authors: William Spears; Matthew Furgerson; John Michael Sweetnam; Parker Evans; Marla Gearing; Marcus Fechheimer; Ruth Furukawa Journal: BMC Neurosci Date: 2014-06-14 Impact factor: 3.288
Authors: Md Sahab Uddin; Anna Stachowiak; Abdullah Al Mamun; Nikolay T Tzvetkov; Shinya Takeda; Atanas G Atanasov; Leandro B Bergantin; Mohamed M Abdel-Daim; Adrian M Stankiewicz Journal: Front Aging Neurosci Date: 2018-01-30 Impact factor: 5.750
Authors: Nathaniel Safren; Amina El Ayadi; Lydia Chang; Chantelle E Terrillion; Todd D Gould; Darren F Boehning; Mervyn J Monteiro Journal: PLoS One Date: 2014-01-27 Impact factor: 3.240
Authors: James C Vickers; Stan Mitew; Adele Woodhouse; Carmen M Fernandez-Martos; Mathew T Kirkcaldie; Alison J Canty; Graeme H McCormack; Anna E King Journal: Curr Alzheimer Res Date: 2016 Impact factor: 3.498